Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Candesartan Cilexetil Formulations
NCT02254447Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2014
- Primary completion
- Jan 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candesartan cilexetil in cardiovascular disease (CVD) (6 arms), sponsored by GSK. Primary endpoint: Composite of pharmacokinetic parameters at 48 hours. Started Dec 2014; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02254447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254447.